D-1040-2019 Class II Terminated
FDA drug recall D-1040-2019 was initiated by Macleods Pharma Usa Inc on Feb 21, 2019 and is designated Class II. Reason for recall: CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient. The recall status is terminated (terminated Sep 28, 2020). Affected quantity: 9695 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 27, 2019
- Initiation Date
- Feb 21, 2019
- Termination Date
- Sep 28, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 9695 bottles
Product description
Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg, 90 count bottles, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. NDC 33342-0052-10
Reason for recall
CGMP Deviation: Presence of NDEA (N-Nitrosodimethylamine), a carcinogen impurity, detected in the active ingredient.
Distribution pattern
NJ, NY, FL
Code information
Lot BLM715A, Jul-19
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1040-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026